Abstract: Compounds are described that are effective in enhancing the efficacy of antimicrobial agents. Also described are methods of using such compounds and compositions that include such compounds. The composition includes a chalcone compound and, optionally, an antimicrobial agent.

Abstract: The present invention relates to an aromatic substituted pentadienoic acid amides and there use in combination of specific amounts of aromatic amides i.e. 4-alkyl-5-(substituted phenyl)-2 (E),4(E)-pentadienoic acid amides, its geometrical isomers or their dihydro or tetrahydro derivatives and an anti-infective drug useful in potentiating the bioefficacy of antiinfective drug. The combination of the present invention is useful in the treatment of certain infections and disease at lower concentration of anti-infectives necessary to inhibit the growth of microbial strains and may also find applications in reducing the resistance in microorganisms.

Abstract: The present invention relates to an aromatic substituted pentadienoic acid amides and there use in combination of specific amounts of aromatic amides i.e. 4-alkyl-5-(substituted phenyl)-2(E),4(E)-pentadienoic acid amides, its geometrical isomers or their dihydro or tetrahydro derivatives and an anti-infective drug useful in potentiating the bioefficacy of antiinfective drug. The combination of the present invention is useful in the treatment of certain infections and disease at lower concentration of anti-infectives necessary to inhibit the growth of microbial strains and may also find applications in reducing the resistance in microorganisms.

Abstract: The present invention relates to an aromatic substituted pentadienoic acid amides and there use in combination of specific amounts of aromatic amides i.e. 4-alkyl-5-(substituted phenyl)-2(E),4(E)-pentadienoic acid amides, its geometrical isomers or their dihydro or tetrahydro derivatives and an anti-infective drug useful in potentiating the bioefficacy of antiinfective drug. The combination of the present invention is useful in the treatment of certain infections and disease at lower concentration of anti-infectives necessary to inhibit the growth of microbial strains and may also find applications in reducing the resistance in microorganisms.

Abstract: The present invention relates to a facile, highly efficient and economical process for the preparation of optically active N-benzyl-3-hydroxypyrrolidine in high yield from a naturally occurring alkaloid vasicine. The natural alkaloid vasicine is used as a precursor of (S)—N-benzyl-3-hydroxypyrrolidine and (R)—N-benzyl-3-hydroxypyrrolidines which can easily be sourced from the medicinal plant Adatoda vasica by the method known in the art and transformed to optical isomers (R) and (S)—N-benzyl-3-hydroxypyrrolidine by the method described in the present invention.

Abstract: Compounds are described that are effective in enhancing the efficacy of antimicrobial agents. Also described are methods of using such compounds and compositions that include such compounds. The composition includes a chalcone compound and, optionally, an antimicrobial agent.

Abstract: The present invention relates to a facile, highly efficient and economical process for the preparation of optically active N-benzyl-3-hydroxypyrrolidine in high yield from a naturally occurring alkaloid vasicine. The natural alkaloid vasicine is used as a precursor of (S)—N-benzyl-3-hydroxypyrrolidine and (R)—N-benzyl-3-hydroxypyrrolidines which can easily be sourced from the medicinal plant Adatoda vasica by the method known in the art and transformed to optical isomers (R) and (S)—N-benzyl-3-hydroxypyrrolidine by the method described in the present invention.

Abstract: The present invention deals with a synergistic herbal composition useful for treatment of rheumatic and musculo-skeletal disorders (RMSDs) comprising a base formulation (50-60%) and plant parts and/or extracts of the plant (40-50%) selected from the group consisting of Withania somnifera, Tribulus terrestris, Phyllanthus emblica and Boswellia serrata optionally along with pharmaceutically acceptable excipients. The herbal formulation is capable of causing simultaneous long term decrease in glycosaminoglycan (GAG) release and aggrecan by cartilage explants resulting in reduction of pain, inflammation, stiffness and low degeneration of bones, joints, muscles and other connective tissues. The present invention further deals with a process for the preparation of the said herbal formulation and a method of treating RMSDs using the formulation up to a high safety level and stable for a long durations.

Abstract: The present invention relates to an immunopotentiating composition and to a composition accelerating the production of interferon-[gamma]. More particularly to a process for preparation of water-soluble Labisia pumila extract and the use of said extract in a pharmaceutical preparation.

Abstract: The present invention relates to a synergistic formulation comprising trans-tetracos-15-enoic acid (t-TCA) and andrographolide (AP) in the ratio ranging between 1:7 to 7:1 (w/w), useful in hepatoprotection; and a process for the preparation of a synergistic formulation comprising trans-tetracos-15-enoic acid (t-TCA) and andrographolide (AP) useful in hepatoprotection, said process comprising steps of grounding the particles of the t-TCA and AP into fine particles, mixing the fine particles in ratio ranging between 1:7 to 7:1 (w/w), and grinding the mixture to obtain formulation, and also, a method of hepatoprotection of a subject using the synergistic formulation comprising trans-tetracos-15-enoic acid (t-TCA) and andrographolide (AP), said method comprising the steps of administering the formulation to the subject.

Abstract: The present invention relates to use of compounds of general formula 1 for anticancerous activity, wherein the said compound being derived semi-synthetically from natural triterpenoic acids known as boswellic acids by the induction of apoptosis thereof cytotoxicity and anti-cancer activity displayed by semi-synthetic analogues of natural triterpenes, known as Boswellic acids. These compounds may be used for the treatment of cancer, alone or in combination with pharmaceutically acceptable or other carriers, displaying cytotoxicity and anti-cancer activity for colon, prostrate, liver, breast, central nervous system (CNS), leukemia and malignancy of other tissues, including ascites and solid tumors. The cancer cell death is mediated by induction of apoptosis and inhibition of cell proliferation at specific doses.

Abstract: The present invention relates to a bioenhancing/bioavailability-facilitating composition comprising: an effective amount of an extract and/or at least one bioactive fraction from Cuminum cyminum; one or more additive selected from drugs, nutrients, vitamins, nutraceuticals, herbal drugs/products, micro nutrients, antioxidants along with pharmaceuticaly acceptable additives/excipient, and optionally, an effective amount of piperine or extract/fraction of piper nigrum or piper longum; and a process for the preparation of such extracts and active fractions from plant Cuminum cyminum.

Abstract: The present invention relates to the use of extracts of Carum carvi as bioenhancers, either alone or in combination with piperine or Zingiber officinale extract to improve the bioavailability of a wide variety of drugs.

Abstract: The present invention relates to a composition useful for hepatocurative effect against CYP 450 bio-activation hepatotoxicity induced by drugs, said composition comprising an extract from Emblica officinalis and optionally pharmaceutically acceptable additives and method of treating drug induced hepatotoxicity

Abstract: The present invention relates to a novel source of microorganism for production of Camptothecin and related camptothecinoids. The invention also discloses its isolation, screening for Camptothecin production, growth, fermentation requirements and chemical analysis of Camptothecin (camptothecinoids).

Abstract: The present disclosure relates to methods and compositions for in vitro cultivation of species of Swertia, e.g. Swertia chirata (Ham.). The disclosure provides culture media comprising Murashige and Skoog (MS) basal culture medium, plant hormones preferably selected from the group consisting of benzyladenine (BAP), gibberellic acid (GA3), and auxins, and other additives, e.g. sucrose and agar. Preferably, auxins are selected from the group consisting of indole acetic acid (IAA), indole butyric acid (IBA), and naphthalene acetic acid (NAA). Individual plant hormone concentrations are preferably from about 0.5 mg/L to about 5.0 mg/L.

Abstract: The present invention relates to a process for the synthesis of racemic nerol oxide i.e. 3,6-dihydro-4-methyl-2-[2-methyl-1-propenyl)-2H-pyran from monoterpene alcohol nerol i.e. cis-3,7-dimethylocta-2,6-diene-1-ol.

Abstract: The present invention relates to a novel synthetic process for the enriched preparation of substituted R(+)?-benzyl-?-butyrolactone (1) as shown in the drawing wherein R1 and R2 independently or in combination represent the following groups: i.e.

Abstract: The present invention relates to the use of bioenhancers to decrease the resistance of microbial strains to anti-infective such an antibiotics and antifungals by potentiating the activities of anti-infective. This may be useful to reduce resistance in bacteria and yeast to aid in the treatment of certain infections and disease and to lower the concentration of antiinfectives necessary to inhibit the growth of microbial strains.

Abstract: The present invention relates to an improved process of analytical and quantitative isolation of withaferin-A from Withania somnifera (Sanskrit: Ashwagandha, English: winter cherry) and other plants and products therefrom, said method comprising steps of selecting most appropriate extraction medium composition, with extraction solvent system consisting of a defined admixture of water and alcohol in a range of proportion of alcohol within a narrow range of (methanol, ethanol etc.